Results 191 to 200 of about 20,052 (248)

SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Although semaglutide 2.4 mg has demonstrated significant weight loss efficacy in clinical trials, real‐world data, particularly with regard to clinically complex and underrepresented populations, remain limited. Objectives The study aims to assess the real‐world effectiveness and patient‐reported outcomes associated with the use of ...
Pierre Bel Lassen, David Jacobi, Marie‐Claude Brindisi, Jean‐Baptiste Bonnet, Fabien Subtil, Sylvie Bin, Fanny Abad, Christine Poitou, Bérénice Segrestin, Séverine Ledoux, Bénédicte Gaborit, Judith Aron‐Wisnewsky, Claire Carette, Mohamed Zerguine, Blandine Gatta‐Cherifi, Didier Quilliot, Emilie Montastier, Antoine Avignon, Héléna Mosbah, Sébastien Czernichow, Emmanuel Disse   +20 more
wiley   +1 more source

Prevention of Weight Regain After GLP1RA Cessation With Oral TIX100

Diabetes, Obesity and Metabolism, EarlyView.
SeongHo Jo, Junqin Chen, Gu Jing, Guanlan Xu, Peng Li, Anath Shalev   +5 more
wiley   +1 more source

Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The REALISED study assessed the clinical outcomes associated with oral semaglutide use in Thai patients with type 2 diabetes (T2D) in real‐world clinical settings. Materials and Methods This retrospective, multi‐centre cohort study included 195 patients with T2D initiating oral semaglutide between April 2022 and December 2023.
Taweesak Wannachalee, Pimjai Anthanont, Supamas Sirisreetreerux, Gurudutt Nayak, Woralak Chumchujan, Yodying Iamsudjai, Supawan Buranapin   +6 more
wiley   +1 more source

Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population. [PDF]

J Manag Care Spec Pharm
Meyer KB, McVeigh M, Chiara AN, Boss KC, Pomfret TC, Semmel K, Bacon R, Nicolas D, Clements K, Alper CJ, Lenz K.   +10 more
europepmc   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome. [PDF]

Drug Des Devel Ther
Ye L, Tang P, Wan H, Zhong X, Chen X, Liu C, Huang R.   +6 more
europepmc   +1 more source

Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis. [PDF]

Online J Public Health Inform
Momeni P, Laverghetta G, Ligatti J, Li L.   +3 more
europepmc   +1 more source

Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor? [PDF]

BMJ Case Rep
Lam B, Tiniakou E, Zhang XR, Assassi S.
europepmc   +1 more source

Diabetic foot ulcer‐related amputation is associated with twofold increased risk of cardiovascular disease: A Korean National Health Information Database Study

Journal of Diabetes Investigation, EarlyView.
Data/Design: Nationwide, population‐based longitudinal cohort using the Korean National Health Insurance Service health checkup database (index 2009–2012) with follow‐up through December 31, 2018. Population/Exposure: Adults with diabetes (N = 1,229,689); DFU‐related amputation at baseline (n = 1,486) vs no DFU‐related amputation.
Jinsun Jang, Bong‐Seong Kim, Hye Won Yang, Heejun Son, Dong Yeon Lee, Min Gyu Kyung, Hwan Jun Jae, Saebeom Hur, Sang Wha Kim, Sanghyun Ahn, Kyung‐Do Han, Soo Heon Kwak   +11 more
wiley   +1 more source

Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes. [PDF]

Curr Diab Rep
Malandris K, Charalampidis K, Loomba R, Sinakos E.   +3 more
europepmc   +1 more source